Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
LGC announces the addition of Quanterix’s HD-X platform to its offering, enabling automated development and performing of immunoassays for ‘unprecedented insights’ into disease biology as well as drug efficacy and safety.
Partnering with airlines is essential, says CSafe executive, as the company signs an agreement to use LOT Cargo’s to airplanes to transporttemperature-sensitive biologics.
LMC Manna is expanding its ability to provide clinical research as a care option to patients by integrating research within its clinics and physician practices – changing the dynamic of how research exists in Canada, says company executive.
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
Johnson & Johnson reaches $20m settlement with two US counties on lawsuits regarding the opioid crisis, exits the upcoming federal trial involving several drug manufacturers.
With nitrosamines back in the headlines due to the recent discovery of contaminants in ranitidine, the EMA releases the five potential causes of the impurities plaguing the industry.
AstraZeneca is implementing N-Side’s recently launched Suite for Clinical Trials to provide ‘a single source of truth’ for safely supplying trials, as more stakeholders are generating more data.
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.
Hospital Angelina Caron of Campina Grande do Sul, Paraná has nearly one million patients, making it the largest hospital in Brazil to join Clinerion’s network.
Firma Clinical Research collaborates with patient advocates to integrate patient-specific information into its clinical trial patient care partner training program, as the company conducts more procedures in-home 'than ever before.'
In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.
The Friends of Cancer Research, in collaboration with Iqvia and other health care research organizations, are working to determine where and when real-world data can be trusted.
US FDA follows up the first generic approval of naloxone nasal spray by encouraging companies to apply with generic applications amid the North American opioid crisis.
PRA Health Sciences’ wholly-owned subsidiary, Symphony Health, has launched a ‘first of its kind’ national market measurement solution integrating prescriber, patient, and payer insights.
The CRO has opened a new clinic in response to demand for early-stage research, specifically for Alzheimer’s Disease, and expanded its footprint in India to conduct studies ‘at favorable pricing with faster timelines,’ say company executives.
A-Alpha Bio raises $2.8m from venture capital firms and angel investors to further develop its technology – and initiate drug discovery and optimization partnerships with pharmaceutical companies.
To improve patient safety and reduce risk, Elsevier is developing an improved drug-drug interaction risk calculator in collaboration with several pharma partners, including Boehringer Ingelheim, Eli Lilly, and Servier.
Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.
InsightRX raises $10m in a Series A funding round to further develop its treatment individualization platform and broaden the therapeutic areas in which it’s applicable.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
PPD is expanding its immunochemistry and biomarker space by 8,000 square feet, the addition of which will also support a dedicated team for one of the company’s global biopharmaceutical clients.
Signant Health is piloting the use of eConsent in a ‘landmark’ study in China, the successful completion of which will encourage further adoption of the technology across the Asia Pacific region, says VP.
Torrent announces that it will recall batches of losartan tablets for the sixth time, after the detection of NMBA exceeding acceptable daily intake levels in latest recall.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
As a day of climate strikes unfolds across the world, we ask how far pharma is engaged on the issue, as well as noting recent innovations that suggest companies are looking at what can be done.
Bayer collaborates with Accenture on the Intient clinical platform, which integrates internal and external clinical data to accelerate drug development insights.
